Melanoma
Dirk Schadendorf, Alexander C. J. van Akkooi, Carola Berking et al. · The Lancet · 2018
Cited by 1,488 works. doi:10.1016/s0140-6736(18)31559-9
Authors
- Dirk Schadendorf
- Alexander C. J. van Akkooi
- Carola Berking
- Klaus Griewank
- Ralf Gutzmer
- Axel Hauschild
- Andreas Stang
- Alexander Roesch
- Selma Ugurel
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Thickness, Cross-Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma
- Cancer statistics, 2017
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Signatures of mutational processes in human cancer
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Final Version of 2009 AJCC Melanoma Staging and Classification